Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

201943 citationsJournal Article

Authors

Karen van Hoeve · KU Leuven

Erwin Dreesen · Cipla (Belgium)

Ilse Hoffman · KU Leuven

Gert Van Assche · KU Leuven

Marc Ferrante · KU Leuven

Ann Gils · Cipla (Belgium)

Séverine Vermeire · KU Leuven

Abstract

Adequate IFX exposure during induction therapy is associated with better clinical and/or biological remission at week 52. Postinduction IFX trough levels were the only predictor for clinical and/or biological remission at week 52.

Topics & Keywords

Inflammatory Bowel Disease Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Pediatric Gastroenterology and Nutrition

Volume 68, Issue 6, pp. 847-853

DOI: 10.1097/mpg.0000000000002265

Field-Weighted Citation Impact: 4.64